SILODOSIN AS A MEDICAL EXPULSIVE THERAPY FOR DISTAL URETERAL STONES IN THE PAKISTANI POPULATION
DOI:
https://doi.org/10.53555/jptcp.v31i2.3611Keywords:
Medical Expulsive Therapy, Renal Colic, Silodosin, Ureteral Calculi, Urolithiasis, Alpha-blocker, LifestyleAbstract
Introduction
Renal stones are a one of leading problems in today’s world. Along with renal stones, ureteral stones also cause significant disturbance in daily living. This is the first research done on the Pakistani population for determining the efficacy of silodosin as MET for distal ureteral stones.
Materials and methodology
This Prospective Cohort study was conducted at Urology Department, KRL Hospital Islamabad from May 2021 to April 2022. Our study comprised 160 individuals with distal ureteric stones of 10mm or less. Silodoso (Silodosin) was prescribed to all patients who came to the urology outpatient department, and their contact information was recorded. Patients were called for follow-up on a weekly basis for up to 3 weeks to make sure that the stone was passing through their urine. The significance of p-value less than 0.05 and odds ratios were examined using the Chi-square test and risk variables for distal ureteral stones. Quality of life was assessed using the Wisconsin Stone (WISQOL) questionnaire.
Results
A whopping 94% of the stones were expelled taking an average of 7.17 days. There are 6.6 times increased risks of forming a stone that is at least 5 mm in diameter in patients between the ages of 41 and 80. Men were 1.4 times more likely than females to have ureteric stones (odds ratio = 1.486, 95 per cent confidence interval [CI] = 1.302-1.696">OR = 1.486). The average quality of life improved after the treatment was 38.87.
Conclusion
According to the results of this study, silodosin is regarded as safe and effective in the treatment of non-complicated distal ureteral stones ranging from 4 to 7 mm in diameter. The cost-effectiveness of silodosin gives it an edge over other alpha-blockers for medical expulsive therapy.
Research Registration: Chinese Clinical Trial Registry (ChiCTR2200060517)
References
Viljoen A, Chaudhry R, Bycroft J. Renal stones. Ann Clin Biochem. 2019 Jan;56(1):15-27. doi: 10.1177/0004563218781672. Epub 2018 Jun 13. PMID: 29792045.
Fwu CW, Eggers PW, Kimmel PL, Kusek JW, Kirkali Z. Emergency department visits, use of imaging, and drugs for urolithiasis have increased in the United States. Kidney Int. 2013;83(3):479-486. doi:10.1038/ki.2012.419
Romero V, Akpinar H, Assimos DG. Kidney stones: a global picture of prevalence, incidence, and associated risk factors. Rev Urol. 2010 Spring;12(2-3): e86-96. PMID: 20811557; PMCID: PMC2931286.
Türk C, Petřík A, Sarica K, Seitz C, Skolarikos A, Straub M, et al. EAU Guidelines on Diagnosis and Conservative Management of Urolithiasis. Eur Urol. 2016 Mar;69(3):468-74. doi: 10.1016/j.eururo.2015.07.040. Epub 2015 Aug 28. PMID: 26318710.
Sridharan K, Sivaramakrishnan G. Medical expulsive therapy in urolithiasis: a mixed treatment comparison network meta-analysis of randomized controlled clinical trials. Expert Opin Pharmacother. 2017 Oct;18(14):1421-1431. doi: 10.1080/14656566.2017.1362393. Epub 2017 Aug 4. PMID: 28756724.
Arda E, Cakiroglu B, Yuksel I, et al. (November 15, 2017) Medical Expulsive Therapy for Distal Ureteral Stones: Tamsulosin Versus Silodosin in the Turkish Population. Cureus 9(11): e1848. doi:10.7759/cureus.1848
Villa L, Capogrosso P, Capitanio U, Martini A, Briganti A, Salonia A, et al. Silodosin: An Update on Efficacy, Safety and Clinical Indications in Urology. Adv Ther. 2019 Jan;36(1):1-18. doi: 10.1007/s12325-018-0854-2. Epub 2018 Dec 6. PMID: 30523608.
Bayar G, Yavuz A, Cakmak S, Ofluoglu Y, Kilinc MF, Kucuk E, et al. Efficacy of silodosin or mirabegron in medical expulsive therapy for ureteral stones: a prospective, randomized-controlled study. Int Urol Nephrol. 2020 May;52(5):835-840. doi: 10.1007/s11255-019-02368-y. Epub 2019 Dec 23. PMID: 31873859.
Yuksel M, Yilmaz S, Tokgoz H, Yalcinkaya S, Baş S, Ipekci T, et al. Efficacy of silodosin in the treatment of distal ureteral stones 4 to 10 mm in diameter. Int J Clin Exp Med. 2015 Oct 15;8(10):19086-92. PMID: 26770537; PMCID: PMC4694437.
Chinese Clinical Trial Register (ChiCTR) - The world health organization international clinical trials registered organization registered platform.
Mathew G and Agha R, for the STROCSS Group. STROCSS 2021: Strengthening the Reporting of cohort, cross-sectional and case-control studies in Surgery. International Journal of Surgery 2021;96:106165.
Ding H, Ning Z, Dai Y, Shang P, Yang L. The role of Silodosin as a new medical expulsive therapy for ureteral stones: a meta-analysis. Ren Fail. 2016;38(9):1311-1319. doi:10.1080/0886022X.2016.1215221
Sahin MO, Sen V, Ongun S, Irer B, Yildiz G. Comparison of the efficacy of silodosin and a terpene combination in the medical expulsive therapy of distal ureteral stones. Int J Clin Pract. 2021;75(4):e13866. doi:10.1111/ijcp.13866
Yuceturk CN, Dadali M, Bagbanci MS, et al. Efficacy of Silodosin Dose in Medical Expulsive Therapy for Distal Ureteral Stones: A Retrospective Study. Urol J. 2017;14(1):2944-2948. Published 2017 Jan 18.
Imperatore V, Fusco F, Creta M, et al. Medical expulsive therapy for distal ureteric stones: tamsulosin versus silodosin. Arch Ital Urol Androl. 2014;86(2):103-107. Published 2014 Jun 30. doi:10.4081/aiua.2014.2.103
Oestreich MC, Vernooij RW, Sathianathen NJ, et al. Alpha-blockers after shock wave lithotripsy for renal or ureteral stones in adults. Cochrane Database Syst Rev. 2020;11(11):CD013393. Published 2020 Nov 12. doi: 10.1002/14651858.CD013393.pub2
Hsu YP, Hsu CW, Bai CH, Cheng SW, Chen KC, Chen C. Silodosin versus tamsulosin for medical expulsive treatment of ureteral stones: A systematic review and meta-analysis. PLoS One. 2018 Aug 28;13(8):e0203035. doi: 10.1371/journal.pone.0203035. PMID: 30153301; PMCID: PMC6112672.
Manjunatha R, Pundarikaksha HP, Madhusudhana HR. A prospective analysis of the cost-effectiveness of alfuzosin, tamsulosin and silodosin for 12 weeks in benign prostatic hyperplasia. Int J Basic Clin Pharmacol. 2016; 5:2481-7.
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Journal of Population Therapeutics and Clinical Pharmacology

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.